Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06240754 · ClinicalTrials.gov registry record · Phase 2
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
A Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06240754: Recruiting Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, sponsored by Washington University School of Medicine.
NCT06240754 is a Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 15 participants, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06240754, a Phase 2 study of Clonal Cytopenia of Undetermined Significance and CCUS Clonal Cytopenia of Undetermined Significance, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Primary Outcome
Hematologic response to enasidenib will be evaluated according to a modified version of the IWG 2006 Criteria for Hematologic Improvement for patients with MDS on clinical trials
Conditions Studied
Interventions
- DRUG Enasidenib
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 2 |
What NCT06240754 shows while recruiting
NCT06240754 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 435-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Clonal Cytopenia of Undetermined Significance appearing as the primary indexed condition, and to 1 intervention - of which Enasidenib is the first listed.
NCT06240754 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06240754 about?
NCT06240754 is a clinical study titled "Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial". Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective t...
What is the current status of trial NCT06240754?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-10-10. Estimated completion is 2029-02-28.
What conditions does trial NCT06240754 study?
This clinical trial studies the following conditions: Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT06240754?
The interventions under investigation include: Enasidenib (DRUG).
Who is sponsoring clinical trial NCT06240754?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06240754 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clonal Cytopenia of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06240754's enrollment target sits among peer trials
15 11th of 11 the lowest of 11 other Clonal Cytopenia of Undetermined Significance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clonal Cytopenia of Undetermined Significance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
RECRUITING · Phase 2
-
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI